Pharma Integrates 2023
BIG HEALTH ISSUES
How do we tackle some of the biggest health challenges, such as chronic conditions, respiratory and cancer?
TECHNOLOGY
How can we use technology to improve health outcomes, improve sustainability and create robust supply chains?
ENABLERS
How do we enable a better Industry, through creating diverse skilled teams, empowering the patient and navigating the economic and regulatory environment?
Registration and Networking
08:15 – 09:05
Registration and Networking
Welcome & Opening Remarks
09:05 – 09:10
Welcome & Opening Remarks
Susan Rienow | Country President UK, Pfizer | President, ABPI
Fireside Chat 1
09:10 – 09:40
Fireside Chat 1
Pharma CEO Plenary Discussion: View from the top – navigating the opportunities and challenges presented by a dynamic UK environment and achieving success.
Speakers include:
Susan Rienow | Country President UK, Pfizer | President, ABPI
Marie-Andrée Gamache | Country President | Novartis UK and Ireland
Dr Antonio Payano | Chief Executive Officer | Bayer UK & Ireland
Interviewed by:
Tamsin Berry | Head of Policy and Partnerships, AreteiaTx | Partner, Population Health Partners
Fireside Chat 2
09:40 – 10:00
Fireside Chat 2
Session 1
10:05 – 10.55
Please join Track 2 or 3
AI – ‘intelligent’ or simply ‘artificial’?
‘AI, ‘data’, and ‘digital’ are the buzzwords of current innovation. How can we…
Have a little ‘patients’
The patient voice is getting louder in all aspects of healthcare, from…
Session 2
11:00 – 11:50
Can the NHS and pharma work together to solve the burden of long-term diseases?
As life expectancy increases, so does the economic burden…
Technology – a new link in a broken supply chain?
The Covid pandemic brought a sharp focus on the fragility of supply chains. Has this driven…
Britain’s got talent?
As our ability to treat diseases becomes ever more advanced, the skills gap across the pharmaceutical sector…
Networking
11:50 – 12:20
Networking coffee break
Session 3
12:20- 13:10
From ‘sick care’ to ‘health care’
With NHS demand outstripping capacity, we must focus on preventative healthcare. How can we…
Partnering – for better or for worse?
CDMOs and CROs have long been well established players on the pharmaceutical scene. As our ways…
Please join Track 1 or 2
Networking
13:10 – 14:10
Lunch
Session 4
14:10 – 15:00
Please join Track 2 or 3
“Should I ask Dr. Google?”
The role of tech giants such as Google, Amazon, Microsoft and Palantir…
Trialling a new approach to clinical trials
Adaptive trials, decentralised trials, virtual trials … many new clinical trials models…
Session 5
15:05 – 15:55
Can ‘rare’ disease treatments become commonplace?
12% of global clinal trials for rare disease cell and gene therapies…
Big CDMO, Small CDMO
The CDMO industry is evolving. With the model of the “mega CDMO” emerging, how will this shape the contract manufacturing landscape, and what are the implications for competition among smaller and speciality CDMOs?
But does it sell?
Regulatory and commercialisation strategies can make or break the success of new treatments. How can we…
Networking
15:55– 16:55
Drinks Reception
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.
Pharma Integrates 2023
Registration and Networking
08:15 – 09:05
Welcome & Opening Remarks
09:05 – 09:10
Susan Rienow | Country President UK, Pfizer | President, ABPI
Fireside Chat 1
09:10 – 09:40
Fireside Chat 1
Pharma CEO Plenary Discussion: View from the top – navigating the opportunities and challenges presented by a dynamic UK environment and achieving success.
Speakers include:
Susan Rienow | Country President UK, Pfizer | President, ABPI
Marie-Andrée Gamache | Country President, Novartis UK and Ireland
Dr Antonio Payano | Chief Executive Officer for Bayer UK & Ireland
Fireside Chat 2
09:40 – 10:00
SESSION 1
10:05 – 10:55
Please join Track 2 or 3
SESSION 2
11:00 – 11:50
Can the NHS and pharma work together to solve the burden of long-term diseases?
As life expectancy increases, so does the economic burden of managing chronic diseases. How can we better diagnose, treat, and prevent long-term conditions such as diabetes, cardiovascular disease, and respiratory disease?
NETWORKING COFFEE BREAK
11:50 – 12:20
SESSION 3
12:20- 13:10
From ‘sick care’ to ‘health care’
With NHS demand outstripping capacity, we must focus on preventative healthcare. How can we turn a ‘sick care’ service into a ‘health care’ service that supports a healthier and wealthier nation?
NETWORKING LUNCH
13:10 – 14:10
SESSION 4
14:10 – 15:00
Please join Track 2 or 3
SESSION 5
15:05 – 15:55
Can ‘rare’ disease treatments become commonplace?
12% of global clinal trials for rare disease cell and gene therapies are run in UK. How can we build on the UK’s academic leadership to secure supply chains, increase access, and adapt healthcare systems for C>?
NETWORKING DRINKS RECEPTION
15:55– 16:55
SESSION 1
10:05 – 10:55
AI – ‘intelligent’ or simply ‘artificial’?
‘AI, ‘data’, and ‘digital’ are the buzzwords of current innovation. How can we best apply advances in artificial intelligence, data science, and digital technology to bring better treatments to patients?
SESSION 2
11:00 – 11:50
Technology – a new link in a broken supply chain?
The Covid pandemic brought a sharp focus on the fragility of supply chains. Has this driven a lasting trend for onshoring manufacturing capabilities and embracing new tech to streamline supply? How are distribution models changing and how quickly are we moving to greener supply chains?
NETWORKING COFFEE BREAK
11:50 – 12:20
SESSION 3
12:20- 13:10
Partnering – for better or for worse?
CDMOs and CROs have long been well established players on the pharmaceutical scene. As our ways of working continue to evolve, how has partnering changed?
NETWORKING LUNCH
13:10 – 14:10
SESSION 4
14:10 – 15:00
“Should I ask Dr. Google?”
The role of tech giants such as Google, Amazon, Microsoft and Palantir is increasing in all aspects of our lives. What is the potential for partnering with big tech companies in the pharma and healthcare space?
SESSION 5
15:05 – 15:55
Big CDMO, Small CDMO
The CDMO industry is evolving. With the model of the “mega CDMO” emerging, how will this shape the contract manufacturing landscape, and what are the implications for competition among smaller and speciality CDMOs?
NETWORKING DRINKS RECEPTION
15:55– 16:55
SESSION 1
10:05 – 10:55
Have a little ‘patients’
The patient voice is getting louder in all aspects of healthcare, from self-diagnosis to policy discussion and clinical trial design. What more can be done to engage patient groups and put patients at the centre of their healthcare journey?
SESSION 2
11:00 – 11:50
Britain’s got talent?
As our ability to treat diseases becomes ever more advanced, the skills gap across the pharmaceutical sector continues to grow. How can we upskill our workforce, better manage talent, and encourage diversity to drive innovation?
NETWORKING COFFEE BREAK
11:50 – 12:20
SESSION 3
12:20- 13:10
Please join Track 1 or 2
NETWORKING LUNCH
13:10 – 14:10
SESSION 4
14:10 – 15:00
Trialling a new approach to clinical trials
Adaptive trials, decentralised trials, virtual trials … many new clinical trials models are appearing on the scene. How can the UK deliver more innovative trials across the board to make the most of assets within the NHS?
SESSION 5
15:05 – 15:55
But does it sell?
Regulatory and commercialisation strategies can make or break the success of new treatments. How can we streamline processes to accelerate market access and deliver ‘value’?
NETWORKING DRINKS RECEPTION
15:55– 16:55
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.